This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Raes, A. Articles by Vande Walle, J. Search for Related Content PubMed PubMed Citation Articles by Raes, A. Articles by Vande Walle, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Hazardous Substances DB LISINOPRIL Social Bookmarking                   What's this?

Review: Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children

Department of Paediatric Nephrology University Hospital, De Pintelaan 185, 9000 Gent, Belgium, ann.raes@ ugent.be

Franciska Malfait

Department of Paediatric Nephrology University Hospital, De Pintelaan 185, 9000 Gent, Belgium

Sarah Van Aken

Department of Paediatric Nephrology University Hospital, De Pintelaan 185, 9000 Gent, Belgium

Annick France

Department of Paediatric Nephrology University Hospital, De Pintelaan 185, 9000 Gent, Belgium

Raymond Donckerwolcke

Department of Paediatric Nephrology University Hospital, De Pintelaan 185, 9000 Gent, Belgium

Johan Vande Walle

Department of Paediatric Nephrology University Hospital, De Pintelaan 185, 9000 Gent, Belgium

Objective. To investigate the antihypertensive efficacy, dosing, tolerability and effects on growth of lisinopril (off label-use) in paediatric patients during long-term treatment.

Design. We conducted a retrospective analysis of data from 123 patients treated with lisinopril in a paediatric nephrology clinic over a 9.3-year period. Patients were categorised by age group and predominant clinical diagnosis: hypertension (n=59), renal parenchymal disease (n=27), diabetes mellitus (n=33) and miscellaneous (n=4).

Results. The vast majority were Caucasian (93%) and boys (66%). Mean duration of treatment was 2.0 years. Age at start of treatment ranged from two months to 17.7 years. Mean lisinopril starting and final doses were 0.105 mg/kg/day for hypertensive patients and 0.108 mg/kg/day for patients with renal disease, respectively. The most common adverse event was hypotension (8.6% of the patients). Haematology and serum biochemistry profiles were unaffected by lisinopril. Growth was not different from data recorded by Belgian population studies. In 29 of the 47 hypertensive patients who received lisinopril monotherapy, comparing blood pressure (BP) at baseline and after six months' treatment, mean reductions in systolic/diastolic BP were 19/18 mmHg.

Conclusions. Lisinopril was well tolerated in paediatric patients. Doses of 0.1 mg/kg/day produced clinically significant BP reduction in hypertensive patients.

Key Words: ACE inhibition • lisinopril • paediatrics • hypertension • tolerability

Journal of Renin-Angiotensin-Aldosterone System, Vol. 8, No. 1, 3-12 (2007)
DOI: 10.3317/jraas.2007.004


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?